Holen Sie sich die Stockscreener-App
14.70
1.66%
0.24
Handel nachbörslich:
14.70
Denali Therapeutics Inc Aktie (DNLI) Neueste Nachrichten
Is Denali Therapeutics Inc. subject to activist investor interestTrade Volume Report & AI Optimized Trade Strategies - thegnnews.com
Denali Therapeutics Inc. Stock Approaches Key Moving Average2025 Valuation Update & Community Verified Swing Trade Signals - sundaytimes.kr
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 - MSN
Denali therapeutics’ Ho Carole sells $52k in stock - Investing.com
Denali Therapeutics COFO Schuth sells $39884 in stock - Investing.com
XTX Topco Ltd Lowers Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Elliott Wave Theory Predicts Pullback in Denali Therapeutics Inc.July 2025 Reactions & Community Consensus Picks - beatles.ru
Is now a turning point for Denali Therapeutics Inc.July 2025 Big Picture & Safe Entry Momentum Stock Tips - Newser
What makes Denali Therapeutics Inc. stock price move sharplyJuly 2025 Earnings & Smart Investment Allocation Insights - Newser
Earnings visualization tools for Denali Therapeutics Inc.Weekly Profit Summary & Weekly Momentum Picks - Newser
Technical signs of recovery in Denali Therapeutics Inc.Dividend Hike & Weekly Consistent Profit Watchlists - Newser
Denali Soars 11% on Biotech Sector Turmoil: What’s Fueling This Surge? - AInvest
Using data filters to optimize entry into Denali Therapeutics Inc.Stock Trading Session Highlights and Summary - Newser
Denali Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowSummary of Consistent Growth Stock Picks - Newser
Denali Therapeutics shares fall 3.52% intraday after reporting mixed Q2 2025 results and regulatory updates. - AInvest
H.C. Wainwright Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Denali Therapeutics Inc. SEC 10-Q Report - TradingView
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
FDA Fast-Tracks Denali's Breakthrough Hunter Syndrome Drug as Pipeline Expands - Stock Titan
Possible Bearish Signals With Denali Therapeutics Insiders Disposing Stock - 富途牛牛
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $32 - 富途牛牛
Denali Therapeutics (DNLI) to Release Quarterly Earnings on Thursday - Defense World
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards? - The Globe and Mail
Is Denali Therapeutics Inc. a good long term investmentMaster stock selection with insider knowledge - Jammu Links News
How strong is Denali Therapeutics Inc. company’s balance sheetCapitalize on momentum stocks before they peak - Jammu Links News
What are Denali Therapeutics Inc. company’s key revenue driversInvest smarter with daily market updates - Jammu Links News
What institutional investors are buying Denali Therapeutics Inc. stockFree Technical Analysis Support - Jammu Links News
What is Denali Therapeutics Inc. company’s growth strategyConsistent triple-digit returns - Jammu Links News
Is Denali Therapeutics Inc. stock overvalued or undervaluedAchieve unparalleled market performance - Jammu Links News
Does Denali Therapeutics Inc. stock perform well during market downturnsMaximize gains with expert trading strategies - Jammu Links News
How does Denali Therapeutics Inc. generate profit in a changing economyMarket-leading profit generation - Jammu Links News
Backtesting results for Denali Therapeutics Inc. trading strategiesForecast Model for Intraday Buy Signals - Newser
How volatile is Denali Therapeutics Inc. stock compared to the marketFree Daily Trading Room Entry - Jammu Links News
What is the risk reward ratio of investing in Denali Therapeutics Inc. stockSky-high return potential - Jammu Links News
Is Denali Therapeutics Inc. a growth stock or a value stockAccelerated financial growth - Jammu Links News
What are analysts’ price targets for Denali Therapeutics Inc. in the next 12 monthsInvest smarter with cutting-edge analytics - Jammu Links News
Is it the right time to buy Denali Therapeutics Inc. stockTransform your portfolio with high-yield stocks - Jammu Links News
DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation - MSN
Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy - Insider Monkey
Price momentum metrics for Denali Therapeutics Inc. explainedStock Portfolio Allocation Guidance for Volatile Markets - metal.it
11 Best Future Stocks to Buy Now - Insider Monkey
Biogen’s BIIB122 Study: A New Hope for LRRK2-Associated Parkinson’s Disease - TipRanks
Oppenheimer Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Can Denali Therapeutics Inc. Rally Enough to Break EvenReal Profit Trade Plan Suggestions Shared Widely - metal.it
Volume Surge May Signal Institutional Interest in Denali Therapeutics Inc.Trade Setups With Clear Risk Limits Highlighted - metal.it
Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of “Buy” by Brokerages - Defense World
What are the technical indicators suggesting about Denali Therapeutics Inc.Real Time Guidance For 2025 - jammulinksnews.com
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):